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Abstract
In this study, for the first time, we have reported a sustained transdermal drug delivery from thermoresponsive poloxamer depots
formed within the skin micropores following microneedle (MN) application. Firstly, we have investigated the sol–gel phase
transition characteristics of poloxamers (PF®127, P108, and P87) at physiological conditions. Rheological measurements were
evaluated to confirm the critical gelation temperature (CGT) of the poloxamer formulations with or without fluorescein sodium
(FS), as a model drug, at various concentrations. Optimized poloxamer formulations were subjected to in vitro release studies
using a vial method. Secondly, polymeric MNs were fabricated using laser-engineered silicone micromolds from various
biocompatible polymeric blends of Gantrez S-97, PEG 10000, PEG200, PVP K32, and PVP K90. The MN arrays were
characterized for mechanical strength, insertion force determination, in situ dissolution kinetics, moisture content, and penetration
depth. The optimized MN arrays with good mechanical strength and non-soluble nature were used to create micropores in the
neonatal porcine skin. Microporation in neonatal porcine skin was confirmed by dye-binding study, skin integrity assessment,
and histology study. Finally, the in vitro delivery of FS from optimized poloxamer formulations was conducted across non-
porated vs microporated skin samples using vertical Franz diffusion cells. Results concluded that permeation of FS was sustained
for 96 h across the MN-treated skin samples containing in situ forming depot poloxamer formulations compared to non-
microporated skin which sustained the FS delivery for 72 h. Confocal microscopic images confirmed the distribution of higher
florescence intensity of FS in skin tissues after permeation study in case of MN-treated skin samples vs intact skin samples.
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Introduction
Skin being a large and accessible organ is considered an at-
tractive route for the administration of a wide variety of drug
molecules, proteins, and vaccines. It also plays an important
role as a barrier against many unwanted and foreign sub-
stances [1, 2]. Conventional transdermal delivery through skin
provides a promising alternative to parenteral and oral
delivery and provides many advantages such as painless de-
livery, bypassing first-pass metabolism, patient accessibility,
and compliance [3, 4]. Despite the multiple advantages of this
route, it also encountered some problems of poor permeability
and low bioavailability; therefore, to date, approximately 20
active pharmaceutical agents were delivered through this route
mostly in the form of transdermal patches that are commer-
cially available. Due to the structural components of the skin,
transdermal drug delivery remained a challenging task [5].
The stratum corneum (SC) layer of the skin, the outermost
lipophilic skin layer (10–15 μm) composed of dead
keratinocytes held together, has been proved to be the main
physical barrier for drug flux across the skin [6, 7].
A number of strategies have been adopted by the re-
searchers to bypass the SC barrier to enhance and sustain drug
delivery via this route [8]. However, in the case of parenteral
sustained release formulations, some issues remain unad-
dressed such as avoidance of burst release, toxicity issues,
and variance in implant microstructure and shape thus limiting
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their practical use [9, 10]. Moreover, enhancement techniques
that has also been widely explored to improve permeation
and/or overcome the physical barrier to drug delivery such
as iontophoresis (electrical energy), microneedles (MNs), la-
ser ablation, sonophoresis (ultrasound), radiofrequency abla-
tion, microdermabrasion, and thermal ablation have their own
limitations [11–13].
MNs (15–2000 μm in height) are attractive micron-sized
minimally invasive third-generation devices which have
been developed and utilized over a decade ago. MNs have
been extensively investigated for a large range of molecules
to enhance their transdermal/intradermal delivery [14–16].
MNs bypass the SC layer to penetrate into the epidermis
layer leading to creation of hydrophilic, interstitial fluid–
filled conduits (microchannels/micropores) of micron-sized
in the skin that goes deep enough to overcome the physical
skin barrier but avoid contact with the nerve endings in the
dermis layer [1]. These microchannels have the ability
enough to allow the passage of loaded host molecules of
variable size, e.g., cosmeceuticals [15], vaccines [16],
monoclonal antibody [17], proteins and peptides [17, 18],
and small molecules enough to evade skin irritation, dam-
age, and infection [19, 20].
MNs can be fabricated by using different types of materials
(e.g., stainless steel, silicon, glass, maltose, titanium, and poly-
mers) and in a variety of designs (coated, hollow, solid, dis-
solvable), geometries to overcome SC and deliver drug to the
target site in the skin or eye [4, 21–28]. Coated MNs have
been investigated to allow the delivery of various drugs, and
micro- and nanoparticles via transdermal route [23–26].
However, coated MNs are ideal for highly potent drugs as
they provide a tiny surface area for coating [23]. On the other
hand, hollow MNs made up of typically glass, metals, ce-
ramics, and silicon deliver the drugs either by diffusion pro-
cess or by bore opening through pressure [29]. However, clog-
ging and loss of volume can occur during hollow MN appli-
cation [30–32].
Dissolving polymeric MNs have shown promising strategy
for transdermal drug and gene delivery [23, 33]. Dissolving
MNs have been fabricated from polymers and biopolymers
maltose, trehalose, polyvinylpyrrolidone (PVP), sucrose,
polyglycolic acid (PGA), poly (vinylpyrrolidone-co-
methacrylic acid) (PVPMAA) polylactic-co-glycolic acid
(PLGA), sodium hyaluronate, poly (methyl vinyl ether-
maleic anhydride), and chondroitin sulfate [34–36].
However, these types of MNs must have enough mechanical
strength to create the microchannels in the skin.
Thermoresponsive polymers provide in situ forming gels
upon injection to provide sustained delivery without undergo-
ing invasive surgical procedure [37]. Among these
poloxamers or pluronics, a PEO–PPO–PEO tri-block copoly-
mers represent a series of central chain of polyoxypropylene
(PPO) and two identical lateral hydrophilic chains of
polyoxyethylene (PEO) [38, 39]. They have been widely used
as in situ forming carrier due to their unique sol–gel transition
behavior in aqueous solution in response to temperature
change at skin (32 °C) and body temperature (37 °C) [1]. At
room temperature (< 30 °C), the aqueous solutions remain in
sol state; however, at certain temperature (> LCST, 32 °C) and
concentration, it converts into gel form forming a depot sys-
tem [40]. Pluronics are FDA-approved biocompatible poly-
mer for oral, injectable, topical, inhalation, and ophthalmic
preparation [3, 41]. Recently, Sivaraman et al. [3] reported
the formation of in situ forming hydrogel MNs using
Pluronic PF127 loaded with a model drug for sustained deliv-
ery. However, to date, no MN-assisted in situ forming depots
from thermoresponsive poloxamer materials have been
reported.
For the first time, in this study, we reported the forma-
tion of depots of thermoresponsive poloxamers within the
micropores of the skin tissues using MNs to sustain trans-
dermal drug delivery. Briefly, MNs were fabricated from
different polymers with varying heights and characterized
for its mechanical strength, moisture content, and in situ
dissolution kinetics in porcine skin. Optical coherence to-
mography (OCT) and scanning electron microscopy (SEM)
were used to study the morphology of the MNs. Poloxamer
solutions with/without fluorescein sodium (FS) were pre-
pared and investigated for its rheological properties.
Selected poloxamer formulations were tested for its in situ
depot formation in the micropores created by MNs, and
in vitro release was evaluated using vertical Franz diffusion
cells. Following in vitro release studies, confocal laser mi-
croscopy was used to study the depth of penetration of FS
in the neonatal porcine skin. The barrier integrity of hair-
less neonatal porcine skin was assessed with transepidermal
water loss (TEWL) before and after MN treatment. Fourier
transform infrared spectroscopy (FTIR) was used to per-
form structure analysis of pure materials and synthesized
MN arrays, while scanning electron microscopy (SEM)
was used to study the morphology of the MNs. Figure 1
indicates the schematic illustration of poloxamer-based in
situ microneedle formation, and their drug delivery and
characterization.
Materials and methods
Materials
Gantrez® S-97 (Mw = 1500.000 Da), a copolymer of methyl
vinyl ether and maleic acid polymers, was provided by
Ashland (Surrey, UK). Poly (ethylene glycol) (PEG, Mw=
10,000 Da), fluorescein sodium (FS) MW 376.27 Da, polyvi-
nylpyrrolidone (PVP K32, MW 40,000 Da; PVP K90, MW
360,000 Da), and methylene blue were all purchased from
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Sigma–Aldrich (Dorset, UK). Pluronic® F-127 (poloxamer
407) (MW 12500 Da), Pluronic® F-87 (poloxamer 237)
(MW 7700 Da), and Pluronic® F108 (MW 14600) were pur-
chased from BASF Chemical Company, Ludwigshafen,
Germany. All other chemicals and solvents used were of pure
analytical grade.
Preparation of poloxamer solutions
Poloxamer solutions were prepared using the cold meth-
od. An appropr ia te amount of a l l poloxamers
(poloxamer 407, 237, and 108) with different concentra-
tions, i.e., 15, 20, 25, and 30% (w/w), were slowly
added to cold distilled water (at 4 °C) and maintained
under constant stirring to form poloxamer solutions. The
poloxamer solutions were kept in the refrigerator over-
night until clear solutions were formed. Combinations of
these poloxamers were also prepared with the same
method [39] as shown in Table 1 which indicates the
feed composition ratios of poloxamer formulations and
their gelation temperatures.
Preparation of fluorescein sodium–loaded poloxamer
solutions
For the preparation of FS-loaded poloxamer solutions, FS in
various concentrations was dissolved in already-prepared op-
timized poloxamer solutions at 4 °C maintained under con-
stant stirring as shown in Table 2. The final FS-loaded
poloxamer solutions were then kept in the refrigerator until
clear solutions were formed (5–10 h).
Rheological analysis
The rheological properties of different poloxamer solutions were
analyzed by AR-2000 rheometer (TA instrument, USA) fitted
Table 1 Feed composition, gelation temperature, and viscosity of
variable poloxamer formulations at 25 and 32 °C (n = 3)
Formulations Sol–gel transition
temperature (°C)
Viscosity (Pa s)
25 °C 37 °C
PF 127 w/w
15 > 40 3.25 400.6
20 34.6 593.7 3206
25 28.5 0.07 293.5
30 25.6 485.4 1091.33
P 108 w/w
15 > 40 0.11 0.18
20 38.3 0.09 660.3
25 33.7 0.75 9722
30 29 0.01 218.6
P 87 w/w
15 > 40 0.02 0.08
20 > 40 0.03 2.15
25 32.8 0.04 79.24
30 28.2 0.49 935.16
P108/F87 w/w
10/10 36.6 0.13 4.98
10/15 34.9 274.18 655.82
10/20 30.1 549.87 1003.47
10/25 24.8 0.21 26.72
Fig. 1 Schematic illustration of formation and drug delivery fromin situ depots of poloxomer gels formed in themicropores created by MN application.
Transition loaded into MN pores and formation of in situ gels at skin temperature (32 °C)
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with 40-mm diameter parallel plate and circulating environment
system for temperature control. The rheological characteristics of
these solutions were studied using flow rheology and oscillation
rheology tests in order to define viscosity at room temperature
(20 °C) and at body temperature (37 ± 2 °C). In flow mode,
viscosity as a function of increasing shear rate (0.1–10 1/s) was
observed by conducting the continuous ramp test at 25 °C for
10 min. Temperature ramp test was performed to observe the
change in viscosity along with increasing temperature (20–
40 °C) at frequency of 1 rad/s and shear rate of 0.1 Pa. In oscil-
latory rheology, elastic and viscous moduli (G′ and G″) were
evaluated with temperature ramp (20–40 °C) which in turn give
sol–gel transition temperature (LCST) [41, 42].
In vitro release study from optimized
thermoresponsive poloxamer gels
The in vitro release profile of FS from in situ thermoresponsive
poloxamer gels was calculated by membraneless dissolution
model reported earlier [38]. From each selected FS-loaded
poloxamer solution, 10 g was taken in a glass vial and equili-
brated until gelation (~ 5 min) in digital shaking incubator at 37
± 1 °C. For release study, 5 ml of phosphate-buffered saline
(PBS) was poured gently on the top of the gels not to disturb
the gel surface layers. The samples (2 ml) for release quantifica-
tion were collected at regular time intervals until the gels
remained intact for the specified time period. Each time, fresh
PBS medium (2 ml) was added to the glass vials to maintain the
sink conditions. The drug contents were measured using a fluo-
rescent plate reader (BMG FLUOstar OPTIMA Microplate
Reader, BMG Labtech, Ortenberg, Germany) operated at
37 °C using 493 and 520 nm as excitation and emission wave-
lengths, respectively.
MN fabrication
Aqueous blends of Gantrez® S-97 and PEG10000, Gantrez®
S-97 and PEG200, and PVPK32/PVPK90 were prepared and
poured into laser-engineered silicone micromold to fabricate
MN arrays as reported previously [14, 43, 44]. TheMN arrays
consisted of 361 (19 × 19) conical-shaped needles with an
average height of 600 μm, with base width of 300 μm and
interspacing of 50 μm perpendicular to 0.5-cm2 area. Briefly,
400 mg of polymer solutions was gently poured onto laser-
engineered silicone micromolds and centrifuged for 20 min at
35000×g. MN arrays were then kept at room temperature for
drying for 48 h. After complete drying, the MN arrays were
removed from the molds and the sidewalls of the arrays were
cut and removed with the heated scalpel blade. TheMN arrays
were then kept in a container and sealed with the aluminum
foil until further use. Table 3 indicates the formulation com-
position and dimensions of MNs.
Characterization of MNs
Determination of MN mechanical strength
The mechanical strength of fabricated dissolving MN arrays
was determined by subjecting to predetermined forces for
compression and skin insertion. The MN arrays were subject-
ed to TA-XT2 Texture Analyzer (Stable Microsystems,
Haselmere, UK) in compression mode by employing a range
of predetermined compression forces. Briefly, MN arrays be-
fore subjecting to testing were visualized using a Leica EZ4 D
digital microscope (Leica, Wetzlar, Germany). Then, MN ar-
rays were carefully attached to the texture analyzer moveable
cylindrical probe on the flat stainless-steel baseplate with the
needles in downward directions. The probe of TA-XT2 ana-
lyzer was then lowered in downward direction at a speed of
0.1 mm/s until MNs touched the stainless-steel solid block and
then start exerting the pre-set forces. The pre-set forces hold
the MN arrays in touch with the stainless-steel solid block for
30 s and after reaching the target force the probe moved up-
wards at a speed of 1 mm/s. MN arrays were visualized again
after force applications using the light microscope and height
of the needles were determined. The change in theMNheights
were determined and reported as % reduction in MN heights
vs applied forces. The experiment was run in triplicates [23].
Insertion force determination of MNs in skin tissues
TA-XT2 Texture Analyzer (Stable Microsystems, Haslemere,
UK) was used to investigate the insertion force of fabricated
MN formulations in neonatal porcine skin. The procedure
adopted is same as previously described with minor modifi-
cation for TA-XT2 Texture Analyzer. Briefly, to investigate
the insertion forces, neonatal porcine skin previously obtained
from stillborn piglets was immediately (less than 24 h after its
birth) removed and trimmed to approximately 450–500 μm
with electric dermatome (Integra Life Sciences™, Padgett
Table 2 Effect of variable FS concentration on gelation temperature of
optimized poloxamer formulations (n = 3)
Concentration of fluorescein sodium (% w/w)
Poloxamers (% w/w) 0 0.1 0.3 0.5 0.7
Gelation temperature (°C)
P108 20 38.3 38.9 39.7 40.6 41.8
P108 25 33.7 34.1 34.9 36.1 38.7
PF127 20 34.6 35 36.2 37.7 39
F 87 25 32.8 34.1 35.8 37.9 40.2
P108/87 10/10 36.6 37.4 38.5 39.3 40.5
P108/87 10/15 34.9 35.6 37.9 40.1 41.3
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Instruments, NJ, USA). The skin was then carefully shaved
off to remove the remaining hairs with a disposable blade and
incubated in PBS (7.4) for 1 h at 37 °C. The skin sample was
then placed on a 400-μm-thick dental wax sheet (Anutex®,
Kemdent Works, Swindon, UK) with its dermis upside down
and mounted on wooden block for support. MN arrays were
then carefully attached to the vertical probe of TA-XT2
Texture Analyzer using double-sided adhesive tape. The TA
instrument was set in compression mode with the trigger force
set at various predetermined required forces. The probe was
then moved in a downward direction at a speed of 0.5 mm/s
onto the skin. As the probe came in contact with the skin
tissue, it continued to pierce the skin at the preset speed of
0.5 mm/s until the required force was reached. Upon reaching
the target force, the probe then moved in an upward direction
at a speed of 1 mm/s [23, 45]. Experiments were conducted in
triplicates.
Depth of MN penetration determination in skin
tissues by optical coherence tomography
In order to measure and visualize the depth of penetration in
neonatal porcine skin tissues, further studies were carried out
using optical coherence tomography (OCT) to visualize MN
insertion into neonatal porcine skin in 2D. Briefly, neonatal
porcine skin, which is considered a good model for human
skin in terms of hair sparseness and physical properties, was
obtained from stillborn piglets and immediately (< 24 h after
birth) excised and trimmed to full thickness (1000 μm). The
neonatal porcine skin tissues were hydrated in PBS (pH 7.4)
for 1 h incubated in a water bath at 37 °C and then dried by
wiping off the solution with dry tissue paper. The hydrated
skin tissues were then placed on a Styropor panel. MN arrays
were then inserted in hydrated neonatal porcine skin tissues
using a custom-made applicator device applying force of 20 N
and immediately visualized using an VivoSight® high-
resolution OCT scanner (Michelson Diagnostic Ltd., Kent,
UK). The skin layers were scanned at a frame rate of up to
8B scans (2D cross-sectional scans) per second. 2D images
were converted into 3D representation using an imaging soft-
ware ImageJ® (National Institutes of Health, Bethesda, USA).
The scale of the image files obtained was 1.0 pixels = 4 μm,
thus allowing the accurate measurements of MN penetration
depth [44, 46]. Experiments were run in triplicates and data
was presented as (mean ± SD) 3 replicate measurements of
MN penetration depth.
In situ dissolution kinetics of MN arrays
The fate or dissolution kinetics of fabricatedMN formulations
were investigated in situ in dermatomed neonatal porcine skin.
Briefly, neonatal skin samples were carefully shaved off by a
disposable razor and then thawed in PBS (pH 7.4) for 30 min.
A circular skin sample was then blotted dry with tissue paper
and carefully attached to the donor compartment of the Franz
diffusion cell (FDC-400 flat flange mounted on an FDCD
diffusion drive console providing synchronous with 15-mm
orifice diameter, and kept thermostated at 37 ± 1 °C, Crown
Glass Co. Inc., Sommerville, NJ, USA) with the help of cya-
noacrylate glue (Loctite Ltd., Dublin, Ireland). A piece of
dental wax was then used to hold the Franz diffusion cell
and to support the skin. The MN arrays were then inserted
into the skin section with a custom-made applicator device
(11.0-N force). The assurance of MN array insertion within
the skin was made possible with the application of a circular
steel weight (diameter 11 mm, 5-g mass) and held for the
predetermined time intervals. At each time point, the MN
arrays were removed from the neonatal skin sample, flash
frozen in liquid nitrogen, and kept on storage at − 20 °C until
viewing. For MN arrays, visualization Leica MZ6 dissection
microscope (Leica Microsystems UK Ltd., Milton Keynes,
UK) fitted with a Nikon Coolpix 950 digital camera (Nikon
UK Ltd., Surrey, UK) was used. Before going for in situ dis-
solution study, MN heights were inspected and measured dur-
ing in situ dissolution at each time point; the change in MN
heights was calculated again [47]. The percent reduction in
MN heights was measured and the in situ dissolution was
reported as remaining MN height vs time (sec). All the mea-
surements were made in triplicates.
Determination of water contents of MNs
Q500 Thermogravimetric Analyzer (TA Instruments, Elstree,
Herts, UK) was used for the percentage water content deter-
mination of the MN arrays. MN array samples of 5.0–10.0 mg
were subjected to heating from 20 to 300 °C at a heating rate
Table 3 MN composition, depth of penetration (DOP) in neonatal porcine skin, and moisture contents of different MNs with 19 × 19 arrays and 300-
μm base widths
Sample codes Sample composition Weight ratio (% w/w) Height (μm) Average DOP (μm)
n = 3
Moisture contents (%)
n = 3
PG10000 Gantrez® S-97/PEG10000 10: 7.5% 600 554 ± 38.02 7.00 ± 0.03
PG200 Gantrez® S-97/PEG200 10: 7.5% 400 392 ± 7.40 4.81 ± 0.29
PVP K90:32 PVP K32/PVP K90 15: 20% 600 – 3.2 ± 0.21
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of 10 °C/min. Nitrogen flow rates of 40ml/min (balance purge
gas) and 60 ml/min (sample purge gas) were kept for all the
samples. The obtained experimental data was analyzed with
TA Instruments Universal Analysis 2000 software, version 44
A (TA Instruments, Elstree, Herts, UK). The experiments
were run in triplicates and data reported indicates the mean ±
standard deviation (SD) [23].
Microchannels visualizations by dye-binding study
The pore formation or microchannels in neonatal porcine skin
sample (3 × 3 cm) by MN arrays was evaluated using 1% w/v
methylene blue dye under Leica EZ4 D digital microscope
(Leica, Wetzlar, Germany). Before MN array application, the
porcine skin sample was carefully shaved off using a disposable
razor and then incubated in PBS (7.4) for 30 min. The skin
sample surface was then blotted with the tissue paper to remove
the excess of solution from the surface. The skin sample was
then treated with MN arrays attached with the vertical probe of
TA-XT2 analyzer. Immediately, methylene blue staining was
applied involving a 5-min surface application of few drops of
methylene blue solution on the treated skin followed by removal
of excessive stain using sterile saline swabs and later with alco-
hol swabs. The treated skin sample was visualized again using
Leica EZ4 D digital microscope (Leica, Wetzlar, Germany) [4].
Skin samples without the application ofMN arrays were used as
control and visualized using Leica EZ4 D digital microscope
(Leica, Wetzlar, Germany).
Assessment of skin integrity
The barrier integrity of neonatal porcine hairless skin was
evaluated rapidly before and after poration with MN arrays
by transepidermal water loss (TEWL) assessment. For TEWL
determinations, porcine skin samples (3 × 3 cm) were thawed
in PBS for 30 min. The barrier function of neonatal porcine
hairless skin was evaluated by measuring TEWL using a
VapoMeter (Delfin Technologies Ltd., Kuopio, Finland)
which assess the increase of TEWL after treatment with the
MN arrays. Experiments were run in triplicates and data pre-
sented indicates the means ± SD [4].
In vitro permeation study
In vitro permeation study was conducted for FS-loaded 20% w/
w PF127®-based thermoresponsive gels across the dermatomed
(400 μm) neonatal porcine skin samples using vertical Franz
diffusion cell setup. The drug permeation study was conducted
across intact skin and MN-treated (microporated) skin samples.
The Franz diffusion cells setup consisted of a receptor compart-
ment which was filled with PBS (5 ml) at pH 7.4 with an effec-
tive permeation area of 0.64 cm2 stirred with magnetic bar at
600 rpm and kept thermostated to 37 ± 2 °C. First, the
dermatomed non-porated intact skin samples were mounted on
vertical Franz cells and kept hydrated for 1 h. The skin samples
were then applied 20% w/w PF127®-based thermoresponsive
gels (1000 μl) containing different FS concentrations (0.1% and
0.3%). The donor compartment and sampling arm were sealed
using Parafilm®. At predetermined time intervals, samples of
500 μl were withdrawn from receptor compartment and re-
placed with the equal volume of PBS (pH 7.4) to maintain the
sink conditions. The collected samples were sealed in aluminum
foil and kept in refrigerator for drug quantification using a fluo-
rescence plate reader [3, 23, 44]. The results were expressed as
cumulative % permeation and reported as mean ± SD.
A similar procedure was adapted for evaluation of drug
permeation from gels across MN-treated skin with little mod-
ifications. Briefly, the selected non-soluble hydrogel-based
cross-linked MN arrays (PG10000) were inserted using the
custom-made applicator at a force of application of 11 N and
left in contact for 1 min using a cylindrical stainless steel of
5 g. The MN array was then removed and the microporated
skin samples were then clamped between the receptor and
donor compartment of the Franz cells. A 20% w/w PF127®-
based thermoresponsive gels (1000 μl) containing different
FS concentrations (0.1% and 0.3%) were applied as before
to study permeation across microporated skin samples [3].
Confocal laser microscopy study
The distribution of the FS was investigated in skin samples by
using confocal laser microscopy. After in vitro permeation
study, skin tissues were then thawed with fresh PBS solution
(pH 7.4) for 15min then blotted dry with tissue paper and kept
in sample blocks containing freezing agent (OCT, Sakura
Finetechnical, Tokyo, Japan) and flash frozen in liquid nitro-
gen. Each skin tissue sample was cryosectioned with a cryo-
stat microtome (Richard Allan Scientific, Kalmazoo, MI,
USA) into 40-μm-thick pieces and collected into respective
sections onto glass slides. The skin tissue sections were then
evaluated for drug distribution using confocal laser scanning
microscope (Leica TCS SP2 Confocal Microscope, Leica
Microsystems, UK) fitted with a Nikon Coolpix 950 digital
camera (Nikon UK Ltd., Surrey, UK). A series of confocal
images were extracted into 3D mode using Volocity software
(PerkinElmer, UK) to observe the nature of drug distribution
in skin tissues [23].
Histology studies
The histology of neonatal porcine hairless MN-untreated and
microporated (MNs treated) skin samples was observed using
optical coherence tomography (OCT), i.e., VivoSight® high-
resolution OCT scanner (Michelson Diagnostic Ltd., Kent,
UK). The skin layers were scanned at a frame rate of up to 8B
scans (2D cross-sectional scans) per second. 2D images were
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converted into 3D representation using an imaging software
ImageJ® (National Institutes of Health, Bethesda, USA) [47].
Structural and morphological characterization of MNs
The structural and morphological characterization of pure ma-
terials and fabricated MN arrays was performed using attenu-
ated total reflectance (ATR) FTIR spectroscopy and scanning
electron microscopy (Hitachi TM 3030 digital scanning elec-
tron microscope; JEOL Ltd., Tokyo, Japan).
FTIR spectroscopy
The structure analysis of pure materials and synthesized MN
arrays was performed using FTIR Accutrac FT/IR-4100
Series (Jasco, Essex, UK) at room temperature equipped with
MIRacle™ software from 4000 to 600 cm−1, with a resolution
of 8.0 cm−1. The obtained spectra indicates the result of aver-
aging 180 scans [44, 48].
Scanning electron microscopic analysis
SEM was performed to evaluate the morphology of the fabri-
cated MN arrays. For SEM imaging (Hitachi TM 3030 digital
scanning electron microscope; JEOL Ltd., Tokyo, Japan), the
MN arrays were mounted on aluminum stubs using double-
sided adhesive tape and “silver dag” and coated with gold/
palladium (SC515 SEM sputter coater; Polaron, East
Grinstead, UK). The morphology of fabricated MN arrays
was evaluated before and after subjecting to mechanical test-
ing by TA-XT2 Texture Analyzer (Stable Microsystems,
Haslemere, UK) [48].
Quantitative analysis
Firstly, the standard calibration curve of FS in appropriate
concentration ranges (μg/ml) vs florescence absorbance was
constructed. The concentration of FS in release samples was
quantified using fluorescent plate reader (BMG FLUOstar
OPTIMA Microplate Reader, BMG Labtech, Ortenberg,
Germany) operated at 37 °C using 493 and 520 nm as excita-
tion and emission wavelengths, respectively. For quantifica-
tion of FS, the gain was set at 1000.
Statistical analysis
The data was statistically analyzed by using Student’s t test
and one-way ANOVAwith post hoc comparisons, where ap-
propriate. In all cases, p value less than 0.05 was considered
significant difference. GraphPad PrismVersion 4.0 (GraphPad
Prism Software Inc., San Diego, CA, USA), Microsoft excel
(11.0, Microsoft, 2015), and OriginPro8 were used to analyze
the data.
Results and discussions
Sol–gel phase transition of poloxamer solutions
The sol–gel phase transition temperature of poloxamer solutions
containing PF127, P108, and P87 and their combinations was
confirmed by investigating their rheological properties using
AR2000 rheometer. The phase transition was studied by
conducting the rheological experiments in flow and oscillatory
mode. In flow method, viscosity as function of increasing tem-
perature (25–40 °C) and shear rate (0.1–10 s−1) were observed
by conducting temperature ramp and continuous ramp test. In
oscillatory rheology, elastic and viscous moduli (G′ and G″)
were evaluated with temperature ramp (25–40 °C) which in turn
give sol–gel transition temperature. The rheological properties
of poloxamer solutions were studied to understand and confirm
the thermal gelation in situ at skin temperature (i.e., 32 °C).
These poloxamer solutions loaded with the drug will be depos-
ited in the microchannels/micropores created by MN array ap-
plication, which will undergo in situ sol–gel transition at skin
temperature and act as drug delivery depots.
Flow rheology
Temperature ramp test
In temperature ramp test, viscosity over extended temperature
ramp (25–40 °C) was observed to evaluate and confirm their
sol–gel transition at skin temperature (32 °C). Poloxamer so-
lutions (PF127, P108, and P87) in various concentrations were
prepared in cold distilled water and stored in refrigerator until
clear solutions were obtained. The poloxamer solutions were
then subjected to temperature ramp test using AR-2000 rhe-
ometer (TA instrument, USA) fitted with 40-mm diameter
parallel plate and circulating environment system for temper-
ature control. Table 1 indicates the viscosity of poloxamer
solutions and their combinations at room temperature and
body temperature (37 °C).
Poloxamers or pluronics are triblock copolymers consisting
of poly (ethylene oxide)-b-poly (propylene oxide)-b-poly (eth-
ylene oxide) (PEO-PPO-PEO) components. In our study, we
investigated a range of poloxamer grades (PF127, P108, and
P87) at variable concentrations (15%, 20%, 25%, and 30% w/
w) that consisted of different PEO/PPO molar ratios.
Poloxamers show amphiphilic properties due to their PEO hy-
drophilic block and central PPO hydrophobic component.
Below lower critical gelation temperature (LCGT), poloxamer
aqueous solutions exist in liquid state of low viscosity due to the
hydration of their hydrophilic PEO components. However,
above their LCGTand at selected concentrations, their viscosity
increased sharply with a slight change in temperature. The pos-
sible mechanism behind poloxamer gelation is considered to be
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due to the self-assembly of poloxamer micelles above their
LCGT. At low temperature, the poloxamers exist as unimers
in aqueous solution; however, with the increase in temperature,
the unimers get assembled into micelles and packed into semi-
solid gelled phase. This micellization of unimers is considered
to occur due to the breakage of hydrogen bonds and increased
hydrophobic interaction of dehydrated PPO components with
temperature increase [42].
The poloxamer molecular weights (MWs) and the ratios of
PPO/PEO components are the other parameters that affect the
gelation properties and temperature. With increasing
poloxamer concentrations, the PPO/PEO ratios increased
which in turn lead to quicker micelle formation and gelation.
Moreover, MWof the poloxamers is a key factor that induces
the thermal gelation. As shown in Table 1, PF127 showed an
increase in viscosity at a concentration of 20% w/w and tem-
perature of 34.2 °C. However, poloxamer P108 shows a slight
increase in viscosity at 20% w/w and 38.3 °C, while P87 did
not show sol–gel transition at 20% w/w concentration. In our
study, we have also investigated the combinations of two dif-
ferent poloxamers at various concentrations, MWs and differ-
ent PPO/PEO ratios. As shown in Table 1, P108/87 in con-
centration ranges of 10/10%, 10/15%, and 10/20% induced
thermal gelation in the required temperature range, i.e., 25–
37 °C. Figure 2a–c indicates the change in viscosity of the
poloxamers over an extended temperature range of 25–40 °C.
Continuous ramp test
Continuous ramp test was conducted to investigate the change
in viscosity with increasing shear rate (0–10 1/s) at 30 °C. All
the poloxamers show a decrease in viscosity with increasing
shear rate. This decrease in viscosity is suggested because of
the dissociation of physical entanglements between the hydro-
phobic PPO components. This shows that poloxamers have
thixotropic property and with increasing shear rate lead to
lower cross-link density and gel disruption. Figure 2d indi-
cates the change in viscosity of poloxamers with increasing
shear rate (0.1–10 1/s) at room temperature.
Oscillatory temperature sweep test
In oscillatory temperature sweep test, elastic and viscous moduli
(G′ and G″) with evaluation of temperature (25–40 °C) were
investigated using AR2000 rheometer with circulating water
bath. It is generally known that G′ refers to the elastic behavior
of the material while G′′ indicates the viscous nature of the ma-
terial. Figure 3 indicates the change in elastic and viscousmoduli
(G′ and G″) of poloxamer solutions with temperature change. It
was observed that initially the values of viscous modulus (G″)
were higher. However, with the increase in temperature, a change
from sol–gel was observed with increasing elastic modulus (G′)
that refers to the gel state of the poloxamer formulations. This
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thermal gelation or increase in elastic modulus (G′) is considered
because of the dehydration of the PPO blocks with increasing
temperature. Moreover, change in elastic and viscous moduli (G′
and G″) also depends upon the concentration of poloxamer so-
lutions. As shown in Fig. 3, no significant change in the elastic
modulus (G′) was observed at 15% w/w for all types of the
poloxamer solutions in the required temperature range of 25–
37 °C. Poloxamers (P108 and P87) did not show an increase
in elastic modulus (G′) at 20% w/w as indicated in Fig. 3b, c.
However, PF127 showed (Fig. 3a) an increase in elastic modulus
(G′) at 20% w/w concentration. This is due to the higher hydro-
phobic PPO ratios in the amphiphilic structure of PF127 which
quickly undergoes micellization and gel formation.
Effect of FS loading on LCGT of poloxamer
formulations
Effect of FS loading on the LCGT of optimized poloxamer
formulations was investigated at various FS concentrations,
mixed with pre-formulated poloxamer solutions before sub-
jecting to rheological analysis. Table 2 indicates the effect of
variable FS concentrations on CGT of the poloxamer formu-
lations. It was observed from the results displayed in Table 2
that FS addition increased the CGT of poloxamer formula-
tions. This is because FS is hydrophilic in nature and, with
its addition, the hydrophilic interactions between the
polymer–polymer and with the surrounding water molecules
dominate over the hydrophobic forces, due to which relatively
higher temperature is required to induce the dehydration of the
PPO components and in turn thermal gelation.
In vitro release experiments from optimized
thermoresponsive poloxamer gels
Release study from optimized FS-loaded poloxamer gel formu-
lations was conducted in PBS (7.4) at 37 ± 1 °C. The FS loaded
(at variable concentrations) of optimized poloxamer formula-
tions (10 g) were transferred to a glass vial and equilibrated until
gelation (~ 5 min) in digital shaking incubator at 37 ± 1 °C. In
general, a biphasic release profilewas observed for all poloxamer
formulations containing variable FS concentrations. Initially, the
poloxamer formulations showed a burst FS release within the
first hour of sampling followed by sustained release. The initial
burst release of FS is suggested because of the drug presence on
gel surface or in the voids of the gel surface layers. Moreover,
poloxamer formulations showed concentration-dependent re-
lease of FS for variable durations. Figure 4 shows the in vitro
release profile of FS from all poloxamer formulations. As shown
in Fig. 4a, which indicates the release profile of 25% P108 con-
taining FS at variable concentrations (0.1%, 0.3%, and 0.5% w/
w), concentration-dependent release was observed. It was found
that 0.1% and 0.3% FS-loaded 25% P108 formulation provides
97 ± 0.22% and 99 ± 0.46% release during 16 h, respectively,
while 0.5% FS-loaded 25% P108 formulation provides 98 ±
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0.16% release for 20 h. Similarly, for poloxamer 25% P87, drug
release was studied for two different concentrations (0.1% and
0.3%) and the results are displayed in Fig. 4b. Moreover, release
from poloxamer PF127 was comparatively for a longer time.
Figure 4c indicates the release profile of 25% PF127 containing
FS at variable concentrations (0.1% and 0.3%). It was observed
that 0.1%FS-loaded 25%PF127 holds the release of 97 ± 0.19%
for 20 h, while 0.3% FS-loaded 25% PF127 provides 98 ±
0.92% release for 24 h. It was observed that after the maximum
duration, all the poloxamer depots start dissolving due to the
dominant hydrophilic interactions and the gels in the release
medium did not remain intact. However, based on the in vitro
release profile, it was concluded that poloxamer 25% PF127
provides the best release for comparatively longer duration and
was selected to be used as the drug delivery vehicle further in
in vitro permeation study.
MN array fabrication
In this study, a wide range of polymers were screened in com-
binations and in different concentration ratios for the success-
ful preparation of MN arrays. Table 3 summarizes the feed
composition of fabricated MN array formulations. For the
preparation of MN array formulations, laser-engineered sili-
cone micromold templates with 19 × 19 needles per square
grid and of two variable heights were used. Moreover, the
MNs were fabricated from a variety of polymers including
Gantrez® S-97, PEG10000, PEG200, PVP K32, and PVP
K90 in various weight ratio combinations as shown in
Table 3. However, only the MN array formulations with good
mechanical strength (after mechanical testing) and higher
heights (600 μm) were selected for further studies. Figure 5
indicates the digital microscopic images of fabricated MN
array formulations.
Characterization of MN arrays
Mechanical testing of MN arrays
The mechanical properties of fabricated MN array formula-
tions (PG10000, PG200, and PVP K90:32) were tested using
the Texture Analyzer. The fabricated MN arrays were subject-
ed to two predetermined compression forces at 10 N and 20 N
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for 30 s. Figure 5a indicates the digital images of the PG10000
MN arrays before and after application of compression forces.
It was found from the mechanical testing that the PVP-based
MN arrays (PVP K90:32) showed more fragile and brittle in
nature. As the compression force was applied, a progressive
decrease in the MN heights was observed and was visualized
using a Leica EZ4D digital microscope (Leica, Wetzlar,
Germany). It was observed that MN arrays composed of
Gantrez® S-97 and PEG200 (PG200) showed some good
mechanical strength at all compression forces. However, the
MN array formulation based on Gantrez® S-97 and
PEG10000 (PG10000) showed the maximum mechanical
strength against all the predetermined compression forces.
Therefore, it was noted that MN arrays fabricated from high
MWs PEG10000 (7.5%) and Gantrez® S-97 (10%) provide
the best MN formulation with respect to their mechanical
strength and creating pores in the neonatal porcine skin.
Notably, no MN arrays were fractured or broken during the
experiment and rather a compression of needle tips was ob-
served. The reduction in the tips’ heights was calculated using
digital microscope (Leica, Wetzlar, Germany) and the data
was displayed as % reduction in MN heights vs applied
compression forces as shown in Fig. 6A. Based on their good
mechanical strength, PG10000 MN formulation was selected
for further studies.
Insertion force determination
The key factor in the successful applications or insertion of
dissolvingMN arrays to any biological tissue is their ability to
withstand the applied forces. The required insertion forces for
MN arrays into neonatal porcine skin were determined using
texture analyzer. MN penetration into the skin tissue requires
an appropriate force so that the MN arrays must have the
ability to pierce the SC and create the micropores for the
deposition of thermoresponsive solutions. The solutions will
convert into gel at skin temperature in the microchannels and
will act as drug delivery cargos. In this study, we select
PG10000 MN formulation (19 × 19 square grid, 600-μm
height) with total needles of 361 per 0.5-cm2 area owing their
good mechanical strength as analyzed by mechanical testing.
Figure 6B indicates the required insertion force of 5, 10, 15,
20, and 30 N per MN array vs insertion depth. It was observed
from the results in Fig. 6B that with the increase in applied
(A) (B)
(C) (D)
(E)
Fig. 5 Digital microscopic
images of fabricatedMN arrays. a
Gantrez® S-97 and PEG10000
(PG10000 MN arrays) before
mechanical testing. b PG10000
MN arrays after subjecting to
mechanical testing. c MN arrays
fabricated from PVP K90 and
K32 (PVP K90:32). d PG10000
MN arrays at lower resolution. e
MN arrays fabricated from
Gantrez® S-97 and PEG200
(PG200)
Drug Deliv. and Transl. Res.
insertion force/array, the MN penetration or insertion efficien-
cy also increased. The highest penetration depth was found for
the higher forces, i.e., 20 N/array and 30 N/array.
Skin integrity assessment
The barrier function of neonatal porcine skin was examined after
physical treatment with MN arrays as assessed with the
transepidermal water loss (TEWL). The VapoMeter (Delfin
Technologies Ltd., Kuopio, Finland) was used which assesses
the increase of TEWL after treatment with the devices. The
VapoMeter consists of sensorswhichmeasure the percent relative
humidity and convert it to a value representative of TEWL.
TEWL measurement assessed the disruption degree of the skin
barrier, and the base TEWL values were recorded for intact neo-
natal porcine skinwhich served as control values. The skin, being
an open system, has continual water loss from its surface, but it is
minimal. When the SC barrier is disrupted, the amount of water
loss from skin increases. Thus, a measurable difference from the
baseline is indicative of disruption of the SC and is an indirect
measure of increased permeability of the skin. From the results as
displayed in Fig. 6C, it was found that TEWL values increased
significantly after treatment with the MN arrays which provide
the evidence of disruption of SC layer and increased TEWL.
Moreover, it was also observed that increased TEWL values also
depend upon the larger no pores and area covered by the pores in
the skin. A similar observationwasmade byNguyen et al. in their
study [2].
Histology study
The histology of the neonatal porcine skin sectionswas evaluated
using VivoSight® high-resolution OCT scanner in order to con-
firm the evidence of perforation with PG10000 MN arrays.
Firstly, the histology of untreated skin sample having intact SC,
epidermis, and dermis layers was observed with high-resolution
OCT scanner. After treatment with MN arrays, the OCT images
of the skin samples showed that PG10000MN arrays effectively
pierce the SC layer, penetrate the epidermis, and find their way to
the dermis layer. It is evident that FS-loaded thermoresponsive
poloxamer solution will flow inside these microchannels by ap-
plying on the skin, will form gel in situ at skin temperature, and
will act as a delivery depot for FS. Figure 7a, b indicates the
histology of the untreated and treated neonatal porcine skin sam-
ples using high-resolution OCT scanner.
Depth of penetration by OCT imaging
The ability of MN array penetration (PG10000 and PG200)
into the neonatal porcine skin tissues was evaluated using
VivoSight® high-resolution OCT scanner. OCT is a non-
invasive imaging technique based on light reflection, and in
this study, the MN arrays were visualized in real time inserted
(A)
(B)
(C)
(D)
Fig. 6 Percent reduction in MNs heights vs applied compression forces
(N) representing the mechanical strength of fabricatedMNs by TA texture
analyzer (mean ± standard deviation (SD) of n = 3, p value = 0.246) (A).
Effect of applied insertion forces (N/array) on insertion/penetration
depths of fabricated MNs into neonatal porcine skin expressed as pene-
tration depths vs applied forces (B). Untreated and MN-treated neonatal
porcine skin integrity assessment by calculating transepidermal water loss
(TEWL) (C). In situ dissolution kinetics of fabricated MN arrays in neo-
natal porcine skin expressed as %MNs height reduction vs insertion time
(sec) (mean ± standard deviation (SD) of n = 3, p value = 0.545) (D)
Drug Deliv. and Transl. Res.
in neonatal porcine skin. OCT imaging indicates not only the
piercing of SC layer of neonatal porcine skin by MN arrays
but it also shows the protruding of MN arrays into the viable
epidermis and dermis layers. Figure 7c–f indicates the OCT
images of in vitro insertion of two MN array formulations
(PG10000 and PG200). The MN array formulations com-
posed of Gantrez® S-97/PEG10000 and Gantrez® S-97/
PEG200 owing to their good mechanical strength and non-
soluble cross-linked nature showed good penetration ability in
full-thickness neonatal porcine skin tissue. Table 3 indicates
the original MN array heights (μm) and average depth of
penetration (μm) into the neonatal porcine skin tissues. On
the other hand, PVP-based MN array formulation (PVP
K90:32) owing to their less mechanical properties (from me-
chanical testing) did not show good penetration ability. This is
suggested because of the rigid and brittle nature of PVP
K90:32MN array formulation that is supposed to quickly start
dissolving in skin tissues after insertion.
In situ dissolution kinetics of MN arrays
The mechanical strength of typical MN array formulations
depends upon several factors mainly polymer MW, polymer
type, concentrations, moisture contents in the formulations,
and preparation methods. In this study, we aim to create mi-
cropores in the skin by application of the MN arrays followed
by the application of drug-loaded thermoresponsive
poloxamer solution that will convert into gel and form in situ
depots. To achieve this goal, the applied MN arrays should
have sufficient mechanical strength to remain undissolved for
a specific time period after insertion into the skin. Thus, in
order to investigate the fate or in situ dissolution of fabricated
MN arrays as reported in Table 3 in skin dissolution, studies
were performed. Figure 6D shows the in situ dissolution ki-
netics of fabricated MN arrays. Our data revealed that PVP-
based MN arrays (PVP K90:32) depict faster dissolution in
the interstitial fluid of skin as compared to PG200 and
PG10000 MN arrays. The results showed that PVP K90:32
MN arrays start dissolving in 30 s and completely dissolved in
120 s. This dissolution pattern of PVP K90:32 MN arrays
confirmed the results from mechanical testing which showed
the rigid and brittle nature of PVPK90:32MN arrays with less
mechanical strength. Moreover, some previous studies, in
which they utilized PVP-based MNs, also report the faster
dissolution in the interstitial fluid of skin [20]. Figure S1a
shows the digital microscopic images of PVP K90:32 MN
arrays before subjecting to in situ dissolution and during dis-
solution study at different time intervals. On the other hand,
DOP=554 um DOP=711 um
DOP=392 um DOP=318 um
(A) (B)
(C) (D)
(E) (F)
Microchannels
Fig. 7 Histology of untreated
porcine skin (a) and MN-treated
neonatal porcine skin indicating
the piercing of SC layer (b).
Average depths of penetration of
fabricated MN arrays into neona-
tal porcine skin tissues by optical
coherence tomography (OCT) (c,
d, e, and f). Data indicates the
mean ± standard deviation (SD)
of n = 3. DOP stands for “depths
of penetration”
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PG200 MNs showed some good mechanical strength as com-
pared to PVP K90:32 MN arrays and dissolved completely in
240 s as shown in Fig. 6D. In contrast, we also found that
PG10000 MN arrays start dissolution in a similar pattern in
the interstitial fluid of neonatal porcine skin but showed a
slower rate of dissolution of all MNs formulated. It was noted
that PG10000 MN arrays started slower dissolution and re-
main non-soluble due to their cross-linked nature for more
than 1 min. The PG10000 MNs dissolved completely in
360 s which in turn indicate their good mechanical strength
due to cross-linked nature as confirmed bymechanical testing.
Figure S1b shows the digital microscopic images of PG10000
MN arrays before subjecting to in situ dissolution and during
dissolution study at different time intervals. From in situ dis-
solution study, it was concluded that due to the non-soluble
cross-linked nature of PG10000 MN arrays, they can be used
as tools for creating micropores during permeation study
across the skin.
Microchannels visualization
The pores or microchannels created in neonatal porcine skin
followed after MN array treatment were visualized by staining
the MN array–treated skin with 1% methylene blue staining.
Since methylene blue, a hydrophilic dye is absorbed by the
aqueous microchannels (due to the presence of interstitial flu-
id) created by PG10000MNs treatment (600-μm height) with
total needles of 361 per 0.5-cm2 area stained the channels
blue. Figure S2a, b indicates the untreated porcine skin and
skin sample treated with MN arrays. Methylene blue staining
confirmed the poration of SC and uniformity of the pores
caused by PG10000 MN arrays which shows the sharpness
of the MN arrays.
Moisture contents determination
The role of moisture contents is obvious and has high impact
on the mechanical properties of MN arrays. The presence of
moisture highly affects the flexibility, rigidity, and dissolution
kinetics of MN arrays. The moisture contents of fabricated
MN arrays were determined using thermogravimetric analysis
and displayed in Table 3. It was observed that PVP-basedMN
arrays (PVP K90:32) showed the lowest moisture contents
which reflect their rigidity and brittle nature. On the other
hand, the highest moisture contents were found for PG10000
MN arrays followed by PG200 MN arrays. The presence of
moisture contents also depends upon the concentration of the
polymers used, their MWs, and overall environmental condi-
tions. MN arrays were prepared in normal lab conditions;
however, the moisture contents of these fabricated MN arrays
can be further reduced by preparing these MN array formula-
tions in controlled conditions (humidity and temperature)
followed by drying under low-temperature environment.
In vitro permeation study
The in vitro permeation study was conducted using vertical
Franz diffusion cell to investigate the permeability of the neo-
natal porcine skin of FS. The permeation study was performed
for 20% w/w PF127®-based thermoresponsive gels loaded
with different FS concentrations (0.1% and 0.3%). The per-
meation was first investigated for PF127®-based
thermoresponsive gels across MN-untreated porcine skin
samples. Then skin samples were treated with PG10000 MN
arrays owing to their non-soluble hydrogel-based cross-linked
nature followed by removal of the MN arrays and application
of FS-loaded PF127®-based thermoresponsive gels. The de-
livery of FS was investigated to confirm whether the MN
array treatment followed by in situ forming depots will cause
any change to delivery of FS across the skin. The accumula-
tion of the FS in the receptor compartment of Franz diffusion
cell was observed with time (Fig. 8).
The percentage cumulative permeation profile showed that a
high permeation of FS and for a comparatively longer time was
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Fig. 8 In vitro cumulative permeation profile of 0.1% FS loaded in 20%
w/w PF127®-based thermoresponsive gels across MN-untreated
dermatomed (400 μm) neonatal porcine skin and through microporated
skin samples (a). Permeation profile of 0.3% FS loaded in 20% w/w
PF127®-based thermoresponsive gels across MN-untreated
dermatomed (400 μm) neonatal porcine skin and through microporated
skin samples (b). Results displayed indicates the mean ± SD (n = 3). p
value was < 0.01
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observed across the MN array–treated skin samples for both the
concentrations used. It was observed from the release profile that
0.1% FS loaded in 20% w/w PF127®-based thermoresponsive
gels provided 63 ± 0.51% permeation across MN-untreated
dermatomed skin samples after 36 h, while across MN-treated
skin samples, 71 ± 0.82% permeation was found until 48 h. On
the other hand, it was found that 20% w/w PF127®-based
thermoresponsive gels loaded with 0.3% FS showed 75 ±
0.57% permeation of FS across MN-untreated dermatomed skin
samples and the delivery was saturated at 72 h. In contrast to
MN-treated skin samples, percent permeation found was about
80 ± 0.69% and the permeation was held for 96 h. It is suggested
that FS is hydrophilic in nature and encounter problems in diffu-
sion across the lipophilic SC layer of the skin. However, due to
its small molecular weight, FS releases from gel matrix and
diffuse through the water channels present in the skin.
Moreover, FS has strong binding affinity probably due to the
ionic interactions and three dissociation constants with its three
pKa values, i.e., 2.13, 4.44, and 6.36 respectively. PF127®-based
thermoresponsive gels act as FS depot with its thermogelling
property at skin temperature and provide the release of FS in
sustained fashion. On the other hand, through microporated skin
samples after MN array application due to their non-soluble hy-
drogel-based cross-linked nature, somewhat higher permeation
of FS from 20% w/w PF127®-based thermoresponsive gels was
found for a longer time period as compared to untreated skin
samples at similar concentrations (0.3% FS). This is suggested
because the SC layer of the skin is ruptured by PG10000 MN
array application. The PF127®-based thermoresponsive solution
loaded with FS flow inside the microchannels created by MN
array application diffuse to the hydrophilic dermis layer of the
skin. At skin temperature, the PF127®-based thermoresponsive
solution converts into gel form and acts as reservoir for the FS in
the microchannels of the skin. In this study, the permeation of FS
afterMN treatment was found in more controlled fashion and for
a longer time duration as compared to permeation across untreat-
ed skin samples. In this study, it was confirmed for the first time
that delivery of FS from in situ forming MNs in microporated
sites across dermatomed porcine skin occurs in more sustained
fashion.Moreover, the drug loading is not a limitation in this case
as the formulation that exists is in solution form with encapsulat-
ing drug and takes MNs’ shape to form in situ depots at skin
temperature as opposed to the dissolving MNs wherein drug
loading can affect the microneedles’ mechanical strength.
Distribution of FS by confocal laser microscopy
In order to evaluate the nature of drug distribution,
dermatomed neonatal porcine skin samples were subjected
to confocal laser microscopy after termination of in vitro per-
meation study. The distribution of FS was tracked in both
types of skin samples, i.e., MN-untreated and MN-treated
samples. Confocal images of the porcine skin were observed
for vertical sections and Z stack captures the images in se-
quence of skin sections at different depths (z) from the surface
of the skin to determine the depth of dye permeation. It was
found from confocal images that application of 20% w/w
PF127®-based thermoresponsive solution containing 0.3%
FS on skin surface infiltrated the skin as indicated by flores-
cence shown in Fig. 9a. A decrease in intensity of florescence
was also observed with the increase in channels’ depth. On the
other hand, skin samples were microporated with PG10000
MN arrays due to their non-soluble hydrogel-based cross-
linked nature followed by application of 20% w/w PF127®-
based thermoresponsive solution containing 0.3% FS. In this
case, the poloxamer solution diffused deep inside the channels
taking the encapsulated FS. Penetration depth profile (Z stack
series) shown in Fig. 9b confirmed that FS penetrated deep in
the microchannels with the intense florescence. This is sug-
gested because PG10000 MN treatment pierced the SC layer
(10–15 μm thick) followed by penetration to underlying epi-
dermis layer (50–100 μm thick) and making its way to the
skin dermis. PG10000 MN treatment created pores that
allowed 20% w/w PF127®-based thermoresponsive solution
containing 0.3% FS to penetrate deep into the skin tissues.
Confocal images confirmed the pore formation by MN treat-
ment and permeation of FS encapsulated in 20% w/w
PF127®-based thermoresponsive solution into the deeper tis-
sues of the skin. In our study, the permeation of FS across the
skin was also found by application of 20% w/w PF127®-
based thermoresponsive solution containing 0.3% FS, howev-
er, with lower intensity in the deep tissues, which in turn
suggest its lower permeability with MN-untreated skin.
Chemical characterization of MNs by using FTIR
spectroscopy
To evaluate the crosslinking reaction between the polymers
used in the manufacturing of fabricated MN arrays, infrared
spectroscopy was used. Figure S3 shows the IR spectra of the
pure materials and the fabricated PG10000 MN arrays. The
non-crosslinked hydrogel presents a single peak at ~
1745 cm−1 that can be assigned to the acid carbonyl groups
of Gantrez® S-97. In the FTIR spectra of PG10000, it shows
three different carbonyl peaks. The first peak at ~ 1340 cm−1
can be assigned to the formation of anhydride groups between
adjacent acid groups in the Gantrez® S-97 chains. The second
carbonyl peak (1750 cm−1) indicates the ester carbonyl
formed between the Gantrez® S-97 acid groups and the ter-
minal hydroxyl groups from PEG chains. The third carbonyl
peak as observed out at ~ 1490 cm−1 corresponds to the acid
carbonyl groups. The main difference between uncross-linked
Gantrez® S-97 and cross-linked Gantrez® S-97/PEG10000 is
the new band that can be attributed to the new ester bonds
formed between the Gantrez® S-97 acid groups and the hy-
droxyl groups of the PEG molecules.
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Morphological analysis by SEM
The morphology of the fabricated MNs was analyzed by
SEM. The fabricated MNs were subjected to SEM analysis
before and after mechanical testing of the MNs at various
resolutions. From SEM analysis, it was noticeable that the
needles were uniformly sharp before subjecting to the
mechanical testing by TA texture analyzer and none of the
needles entirely failed due to fracture or prior to mechanical
testing. However, tip bending or breakage was observed for
fabricated MNs after subjecting to compression forces by TA
texture analyzer. Figure 10 indicates the SEM images of the
fabricatedMNs before and after subjecting to mechanical test-
ing by TA texture analyzer.
(A)
(B)
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Fig. 9 Confocal microscopic images (Z stack series) of distribution of
0.3% FS in MN-untreated neonatal porcine skin tissues after
thermoresponsive poloxamers solution application during permeation
study at 72 h (a). Distribution of 0.3% FS in MN-treated microporated
neonatal porcine skin tissues after thermoresponsive poloxamers solution
application during permeation study at 96 h (b)
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Conclusion
In this study, various poloxamer grades with different MWs
and in variable concentrations were investigated for their
phase transition property at skin temperature (32 °C) to form
in situ depots in micropores of skin treated with MN arrays.
The phase transition of poloxamers in designing MN-assisted
in situ forming depots was confirmed by conducting the rhe-
ological study. These in situ forming MN-assisted depots can
be loaded with drug molecules of low and high MWs and can
carry the lower and higher drug concentrations across the
main barrier of the skin, i.e., the stratum corneum. MN arrays
used as a source of microporation in neonatal porcine skin
were fabricated from a variety of polymer materials. The
fabricated MN arrays were subjected to extensive characteri-
zation studies, i.e., mechanical strength, in situ dissolution
study, insertion forces, and moisture contents, and the opti-
mized MN array formulation was selected on their ability to
withstand high compression forces required for pore creation.
Dye-binding study and optical coherence tomography (OCT)
showed the successful skin penetration of MNs and histology
of the microporated skin. Moreover, a comparatively higher
and controlled permeation of FS across MN-treated neonatal
porcine skin was found as compared to untreated skin. The
distribution of FS in skin tissues was successfully tracked by
confocal laser microscopic analysis with higher intensity of
FS in MN-treated skin tissues. Cross-linking of polymers in
MN fabrication and structural confirmation was done by AT-
Fig. 10 Scanning electron
microscopy of PG10000 MN
arrays before mechanical testing.
a × 40 magnification. b × 50
magnification. c × 100
magnification. d × 120
magnification. e SEM analysis
after mechanical testing × 150
magnification. f × 300
magnification
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FTIR analysis. The morphology of the fabricated MNs before
and after subjecting to mechanical testing was observed by
SEM analysis. Finally, it was concluded that sol–gel transition
characteristic of poloxamers can be utilized to create in situ
forming depots in micropores of skin treated with the MNs to
provide the controlled delivery of the active pharmaceutical
agent.
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